MTOR and melanoma: Indeed, the treatment of a melanoma patient experiencing anti-PD1 induced colitis with an mTOR inhibitor (sirolimus) could dampen systemic inflammatory responses and relieve this toxicity while sparing the anti-tumorigenic effects of PD-1 blockade [174].